CARMA, Canada

Registration Status: Completed

Objective: Biobank of blood samples (whole blood, plasma, serum, live PBMC) and cheek swabs collected from participants enrolled in the CARMA cohort. The cohort was funded by two consecutive team grants (to H Cote as nPI): Emerging team grant in HIV therapy and markers of aging (2007-2012) and team grant in Cellular Aging and HIV comorbidities in women and children (2013-2018). Both grants studied markers of cellular aging in persons living with HIV, exposed but uninfected (children born to HIV moms), and controls.

Registered Biobank Name	CARMA
Biobank Leader	Helene Cote
Country	Canada
Email for biobank inquiries	helene.cote@ubc.ca
Principal Investigator	Helene Cote (UBC), Neora Pick (UBC), Deborah Money (UBC), Ari Bitnun (Hospital for Sicj Children, On), Hugo Soudeyns (U of Montreal)
Website
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).